Author:
Perrier Q.,Tuloup V.,Chevallier-Brilloit C.,Bedouch P.,Chanoine S.
Funder
Université Grenoble Alpes
Reference10 articles.
1. IGIV: contents, properties, and methods of industrial production–evolving closer to a more physiologic product;Martin;Int Immunopharmacol avr,2006
2. Basic principles of intravenous immunoglobulin (IVIg) treatment;Stangel;J Neurol sept,2006
3. Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012;Robert;Transfusion (Paris),2015
4. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency;Benbrahim;Eur J Haematol,2018
5. Immunoglobulin replacement therapy in primary and secondary antibody deficiency: the correct clinical approach;Pecoraro;Int Immunopharmacol,2017